Massachusetts Selecta Biosciences' CEO to Retire at the End of 2018
Werner Cautreels, Ph.D., intends to retire effective December 31, 2018. Source: BioSpace
5 Massachusetts Biotechs That Tanked More Than 60% in 2017
This is definitely a list few, if any, companies want to be on. Source: BioSpace
Bay Area's DNAnexus Scores $58M to Accelerate Expansion
The cash will support expansion in translational informatics, clinical trials, and broadened use of biomedical data. Source: BioSpace
2 Underappreciated Biotech Stocks to Buy in 2018
A look at two biopharma companies that fall into this category that investors should check out. Source: BioSpace
Former Pfizer CEO's Boston Startup Centrexion Lands $67M for Ph3 Osteoarthritis Pain Drug
Centrexion closed on a Series D financing worth $67M to develop its knee osteoarthritis drug in Phase III. Source: BioSpace
3 Biotechs Seeking $271M IPO in the New Year
Three biotech companies want to start out the new year with a new start. Source: BioSpace
Optinose Gets $100M Debt Financing From Athyrium Capital Management
At closing of the agreement, $75 million in aggregate principal amount of the Senior Secured Notes were issued. Source: BioSpace
Shanghai's SARI Pays $359M for Italian Cancer Biopharma NMS
The parts expect the closing in the first quarter 2018. Source: BioSpace
The Numbers Are In: Bay Area's Depomed Reveals 328 Job Cuts in WARN Notice
The company's sales department will take the brunt of the layoffs, losing 235 jobs. Source: BioSpace
Celgene Takes a $411M Hit From Discontinuation of Crohn's Disease Trials
Celgene announced back in October that it was discontinuing its GED-0301 program for Crohn's disease and now that decision is costing the company $411M. Source: BioSpace
- Go to the previous page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- …
- 288
- Go to the next page